From bench to bedside
November 8, 2022
The fact that 90% of compounds in clinical trials fail to receive Food and Drug Administration approval doesn’t fully account for the magnitude of the drug discovery challenge. Getting a new drug to the patient is exceedingly hard. Innovative science is not enough to advance patient care. This preclinical challenge must be successfully overcome, yet few scientists have the expertise to do this. Creating a team dedicated to help biomedical scientists successfully traverse the valley of death is essential for bringing a significant discovery to the clinic.